A recent 60-day trial explores how a standardized ashwagandha extract impacts cortisol, triglycerides and blood pressure in adults with mild anxiety and hypertension.
On September 4, 2026, NutraIngredients reported new findings regarding ashwagandha and cardiometabolic health. A recent study published in the journal Stress examined a specific standardized extract called Ashwagen. The researchers wanted to see if targeting stress might directly improve both psychological and physical health metrics over a two-month period.
The randomized and placebo-controlled trial included exactly 60 adults who were specifically dealing with anxiety, perceived stress and hypertension. These participants were not simply healthy volunteers seeking general wellness improvements. They had at least one distinct cardiometabolic risk factor, such as elevated waist circumference, high triglycerides or low HDL cholesterol. They took 600 mg of Ashwagen daily for 60 days to assess potential metabolic shifts.
The researchers proposed that the Ashwagen extract might influence the hypothalamic-pituitary-adrenal axis. This specific biological system regulates how our bodies respond to both physical and mental pressure throughout the day. When facing daily challenges, the adrenal glands release cortisol to help the body respond to immediate demands. This natural process is healthy in short bursts, but chronic activation can lead to systemic problems.
Persistently high cortisol levels can disrupt glucose metabolism, elevate blood pressure and alter lipid profiles over time. Elevated stress hormones can also fundamentally alter how the human body processes energy and regulates hunger signals. Understanding this biological cascade is essential for adults who want to improve their overall metabolic function safely.
At WeightRestart, we know that weight management is never simply a matter of willpower alone. It relies heavily on managing appetite, prioritizing sleep hygiene and navigating environmental factors. Early in our research, we reviewed a study showing how just a few nights of poor sleep could significantly alter appetite hormones. It was a clear revelation.
So many people were meticulously tracking their food but completely ignoring their sleep and stress levels. We immediately shifted our editorial focus to include recovery as a fundamental pillar of weight management alongside nutrition and movement. Understanding how stress hormone rhythms shape a different kind of weight gain is crucial for long-term metabolic health. Without addressing these underlying recovery variables, traditional nutrition plans often become unsustainable.
The fitness industry routinely searches for quick solutions to complex physiological problems like stress and fatigue. Consequently, promising early research on specific plant extracts often gets distorted into guaranteed wellness protocols. Consumers are frequently told that a single capsule can undo months of poor sleep and high anxiety. By analyzing the actual data, we can separate genuine clinical potential from aggressive marketing exaggeration.
Mainstream media outlets often portray stress-reduction supplements as direct weight-loss tools. Some aggressive marketing materials suggest that lowering cortisol will automatically shrink a so-called cortisol belly. However, this specific trial provides no direct evidence that Ashwagen causes weight loss or suppresses appetite. The study simply did not measure body weight, fat mass, lean mass or waist circumference changes.
The published findings do not mean that ashwagandha will prevent emotional eating or produce measurable fat loss. Furthermore, the placebo group in this study also experienced notable improvements during the trial. For example, participants taking the placebo saw a 12.47 percent decline in their Perceived Stress Scale scores. They also experienced a remarkable 22.96 percent decline in clinical anxiety scores on the GAD-7 assessment.
These placebo improvements indicate that expectancy effects or behavioral changes during the trial may have played a significant role. Simply participating in a health study can encourage individuals to build better daily routines and manage their time more effectively. Product differences also matter immensely when evaluating these bold supplement claims. The trial specifically tested Ashwagen, which is a standardized extract supplied by Dr. Willmar Schwabe India Pvt. Ltd.
The trial results cannot be broadly generalized to every ashwagandha powder or unstandardized supplement on the market. Additionally, meta-analytic evidence summarized by outlets like Vitmode shows mixed results regarding stress and cortisol. One analysis found improvements in perceived stress, while another reported significant cortisol reductions but no improvement in subjective stress. These conflicting findings highlight the need to separate biological markers from subjective emotional outcomes.
The trial reported several significant percentage changes in key cardiometabolic markers for the intervention group. Serum cortisol reportedly fell 28.99 percent in the Ashwagen group over the 60-day period. In contrast, the placebo group saw only a 6.6 percent reduction in their cortisol levels. The researchers also monitored lipid measures to assess metabolic changes.
Triglycerides decreased by 13.00 percent in the group taking the Ashwagen extract. The placebo group actually experienced a 2.35 percent increase in their triglycerides during the exact same period. In addition to triglycerides, the researchers also tracked LDL cholesterol changes over the two months. LDL cholesterol declined slightly in both groups, but the reported change was strictly described as not statistically significant.
Blood pressure measurements also shifted favorably for the intervention group during the study window. Systolic blood pressure decreased by 7.11 percent for those taking the standardized extract. Diastolic blood pressure similarly declined by 9.2 percent in the Ashwagen group. The placebo group saw a slight increase in systolic pressure and a slight decline in diastolic pressure.
It is highly important to note that the NutraIngredients report omitted critical context for these figures. The report did not provide absolute baseline values, confidence intervals or exact effect sizes for these metrics. Participants receiving the extract also showed improved scores on the Epworth Sleepiness Scale and the Fatigue Severity Scale. The researchers suggested that reduced anxiety may have translated into better functional well-being for participants with chronic hypertension.
No serious adverse events were reported, and the supplement was described as well tolerated throughout the study. However, a brief 60-day window is not sufficient to establish long-term safety or durable cardiometabolic improvements. People with certain health conditions must remain cautious despite the positive short-term tolerability data. Outlets like All About Supplements note that ashwagandha may interact with medicines for blood pressure, diabetes and thyroid conditions.
Those who are pregnant, breastfeeding or managing autoimmune issues should consult a medical professional before use. Relying on a supplement without proper medical guidance is often why weight loss stalls when underlying health interactions remain unaddressed.
The current findings offer an intriguing early signal regarding stress reduction and cardiometabolic health. However, the investigators themselves formally called for larger and more diverse study populations. Future trials desperately need longer follow-up periods to understand both long-term safety and sustained efficacy. We must see absolute numerical values and clear statistical significance to fully evaluate the actual clinical magnitude.
Until more robust data emerges, this should remain a targeted, medically supervised option rather than standard practice. Prioritizing sleep, stress and recovery through established daily habits remains the true foundation of metabolic health. Targeted supplementation might eventually offer a modest adjunct for some individuals under strict clinical supervision. We will continue monitoring the scientific literature to see if these early signals translate into reliable long-term outcomes.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
